MA71474A - Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine - Google Patents

Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine

Info

Publication number
MA71474A
MA71474A MA71474A MA71474A MA71474A MA 71474 A MA71474 A MA 71474A MA 71474 A MA71474 A MA 71474A MA 71474 A MA71474 A MA 71474A MA 71474 A MA71474 A MA 71474A
Authority
MA
Morocco
Prior art keywords
lasmiditan
migraine
treatment
combination therapy
cgrp antagonist
Prior art date
Application number
MA71474A
Other languages
English (en)
French (fr)
Inventor
Sheena Aurora
Kirk Willis Johnson
John Henry Krege
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA71474A publication Critical patent/MA71474A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA71474A 2017-09-06 2018-08-30 Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine MA71474A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762554726P 2017-09-06 2017-09-06
EP24170976.5A EP4397317A3 (en) 2017-09-06 2018-08-30 Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine

Publications (1)

Publication Number Publication Date
MA71474A true MA71474A (fr) 2025-04-30

Family

ID=63529021

Family Applications (2)

Application Number Title Priority Date Filing Date
MA71474A MA71474A (fr) 2017-09-06 2018-08-30 Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine
MA050073A MA50073A (fr) 2017-09-06 2018-08-30 Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA050073A MA50073A (fr) 2017-09-06 2018-08-30 Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine

Country Status (17)

Country Link
US (1) US20200268735A1 (enExample)
EP (2) EP3678665A1 (enExample)
JP (5) JP6922092B2 (enExample)
KR (2) KR20230025945A (enExample)
CN (3) CN111032044A (enExample)
AU (1) AU2018329568B2 (enExample)
BR (1) BR112020002077A2 (enExample)
CA (1) CA3073996C (enExample)
EA (1) EA202090457A1 (enExample)
IL (2) IL314347A (enExample)
MA (2) MA71474A (enExample)
MX (2) MX2020002554A (enExample)
MY (1) MY205182A (enExample)
SG (1) SG11202001387WA (enExample)
TW (1) TWI754772B (enExample)
WO (1) WO2019050759A1 (enExample)
ZA (1) ZA202000443B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2413933T4 (da) 2009-04-02 2021-08-23 Colucid Pharmaceuticals Inc 2,4,6-trifluor-N-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamid til behandling af migræne via oral eller intravenøs indgivelse
TWI692485B (zh) * 2011-05-20 2020-05-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
CN112022818A (zh) 2014-02-05 2020-12-04 默沙东公司 Cgrp-活性化合物的片剂制剂
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
CA3043772C (en) 2016-12-06 2022-06-07 Colucid Pharmaceuticals, Inc. Hydrates of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and uses thereof as a 5-ht1f agonist
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190374518A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
PH12021551689A1 (en) * 2019-01-20 2022-05-11 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating migraine breakthrough
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited MIGRAINE TREATMENT
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术
JP7499538B1 (ja) 2023-03-29 2024-06-14 ロゴスサイエンス株式会社 慢性疼痛の治療、改善およびセルフケアシステム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002353D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New use
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2005046659A2 (en) * 2003-11-12 2005-05-26 Nps Pharmaceuticals, Inc. Migraine treatments including isovaleramide compounds and serotonin agonists
WO2011123654A1 (en) * 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
AU2017331593B2 (en) * 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
RU2770066C2 (ru) * 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
MX2023008760A (es) 2023-08-02
JP6922092B2 (ja) 2021-08-18
KR20200036919A (ko) 2020-04-07
ZA202000443B (en) 2022-07-27
JP2023029872A (ja) 2023-03-07
CA3073996A1 (en) 2019-03-14
AU2018329568A1 (en) 2020-02-06
NZ761634A (en) 2024-05-31
EA202090457A1 (ru) 2020-06-10
EP4397317A3 (en) 2024-10-16
IL314347A (en) 2024-09-01
CA3073996C (en) 2022-05-31
CN116059204A (zh) 2023-05-05
JP2020530861A (ja) 2020-10-29
TW201919624A (zh) 2019-06-01
JP2021176884A (ja) 2021-11-11
BR112020002077A2 (pt) 2020-07-28
SG11202001387WA (en) 2020-03-30
JP7711255B2 (ja) 2025-07-22
MX2020002554A (es) 2020-07-13
US20200268735A1 (en) 2020-08-27
TWI754772B (zh) 2022-02-11
MA50073A (fr) 2020-07-15
KR20230025945A (ko) 2023-02-23
CN116509861A (zh) 2023-08-01
EP4397317A2 (en) 2024-07-10
WO2019050759A1 (en) 2019-03-14
JP2024109585A (ja) 2024-08-14
JP7480261B2 (ja) 2024-05-09
EP3678665A1 (en) 2020-07-15
MY205182A (en) 2024-10-04
AU2018329568B2 (en) 2021-09-23
IL273031A (en) 2020-04-30
JP7183355B2 (ja) 2022-12-05
CN111032044A (zh) 2020-04-17
JP2025165940A (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
MA71474A (fr) Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine
FR25C1041I1 (fr) Elafibranor pour l'utilisation dans le traitement de la cholangite biliaire primitive
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA50417A (fr) Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang
MA51032A (fr) Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
EP3858977A4 (en) STRAIN FOR THE PREVENTION AND TREATMENT OF METABOLIC DISEASES AND USE THEREOF
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
EP3496666A4 (en) DEVICES AND METHODS FOR TREATING HEART VALVE INSUFFICIENCIES
EP3393475C0 (en) CIFORADENT ALONE OR IN COMBINATION WITH ATEZOLIZUMAB FOR USE IN THE TREATMENT OF CANCER
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
EP3500299A4 (en) USE OF A COMBINATION WITH A BTK INHIBITOR TO TREAT CANCER
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EP3370748A4 (en) THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND / OR PREVENTION OF FOOD ALLERGY
EP3512517A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF ANXIETY AND DEPRESSION
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
EP3481393A4 (en) COMBINATION OF A PD-L ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
FR24C1053I2 (fr) Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique
EP3848022C0 (en) THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION
EP3426254C0 (en) USE OF BRAF INHIBITORS TO TREAT SKIN REACTIONS
MA52231A (fr) Combinaison d'inhibiteurs de lif et d'inhibiteurs de l'axe pd-1 pour une utilisation dans le traitement du cancer
EP3397063A4 (en) USE OF MICRO AND NANOBLAS IN LIQUID PROCESSING
EP3541185A4 (en) USE OF 2-HYDROXYBENZYLAMINE FOR TREATING AND PREVENTING PULMONAL HYPERTENSION
EP3880709A4 (en) DOSING REGIME OF ANTI-LAG3 ANTIBODIES AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF CANCER